Previous published findings provided evidence for the role of the PI3K–NFκB axis in NSCLC cisplatin resistance and suggested that inhibitors targeted against NFκB could provide a promising treatment strategy for patients with NSCLC [101]. Here, NFKB1 is linked to non-small cell lung carcinoma.